6 Generic Products That Are Just As Good

AAA

Is Generic Just As Good?

Money-strapped shoppers are choosing generic over big name brands in their supermarket aisles. Consumers generally agree that generic diapers, toilet paper, condiments and cheese simply aren't worth the savings. However, there are a few generic products that make the grade. Here are 6 generics that are just as good as the real thing.

  1. No results found.
Related Articles
  1. Insights

    How Teva Is Fighting (and Losing) the Big Pharma Battle

    Teva is still the largest generics drugmaker in the world but struggles to catch up with big pharmaceutical companies boosted by brand name drugs.
  2. Investing

    Novartis Eyes $8B Buy of Generic Drug Firm (NVS)

    The potential $8 billion acquisition can help Novartis become the third-largest generic drug company in the US.
  3. Insurance

    How to Profit from the Generic Drug Trend

    Generic drugs are poised to steal market share as patent protections on a number of branded drugs expire. Investors should be ready, too.
  4. Investing

    Generics Won't Be Delayed by Citizen Petition Rule

    The Citizen Petition rule, often used as a tool to delay generic drug launches, was amended by the FDA to stop its misuse.
  5. Investing

    Big Pharma Faces 'Pay For Delay' Lawsuits

    Unless you follow the pharmaceutical and biotech sectors, it’s likely that you’ve never heard of pay to delay. Instead of planning to lose nearly all revenue once the drug goes off patent, the ...
  6. Insights

    Why Are Prescription Drug Prices So High?

    Expensive drugs that don’t have affordable alternatives or generic equivalents are a serious concern today. So why are prescription drug prices so high?
  7. Investing

    Endo Settles FTC 'Pay-for-Delay' Allegations

    Endo resolved a dispute with the FTC alleging that it paid rivals to delay generic drug rollouts.
  8. Investing

    6 Drug Companies With Expiring Patents In 2011

    The 2011 "patent cliff" is approaching and many big name pharmaceutical manufacturers face patent expiration on their core products. Is this a coffin nail or can these companies overcome generic ...
  9. Investing

    Teva Blames FDA Generics Approvals For Its Decline

    The Israeli pharmaceutical giant blames a $6.1B writedown in Q2 on increased competition in the U.S.
  10. Investing

    Big Week Ahead for Big Pharma: Roche, GSK, Sanofi, Mylan

    Big pharma companies eagerly await key decisions on drugs from the FDA next week.
Trading Center